Margaret Dugan

10.7k total citations · 4 hit papers
71 papers, 6.2k citations indexed

About

Margaret Dugan is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Margaret Dugan has authored 71 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 27 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Margaret Dugan's work include Histone Deacetylase Inhibitors Research (12 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Margaret Dugan is often cited by papers focused on Histone Deacetylase Inhibitors Research (12 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Margaret Dugan collaborates with scholars based in United States, Germany and Switzerland. Margaret Dugan's co-authors include Matthew J. Ellis, L. Mauriac, Francis J. Giles, Jörge E. Cortes, Hagop M. Kantarjian, P. Rae, Kapil N. Bhalla, Maher Albitar, Leila Alland and William Mietlowski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Margaret Dugan

69 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine profile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 790 citations Matthew J. Ellis, L. Mauriac et al. Journal of Clinical Oncology profile →
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

1999 608 citations Margaret Dugan et al. Journal of Clinical Oncology profile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 530 citations W. Eiermann, Stefan Paepke et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Margaret Dugan

Since Specialization

Citations

This map shows the geographic impact of Margaret Dugan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Dugan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Dugan more than expected).

Fields of papers citing papers by Margaret Dugan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Dugan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Dugan. The network helps show where Margaret Dugan may publish in the future.

Co-authorship network of co-authors of Margaret Dugan

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Dugan. A scholar is included among the top collaborators of Margaret Dugan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Dugan. Margaret Dugan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antiseizure medication discontinuation: A mixed-methods exploration of factors considered by patients when approaching decision-making 2025 ·Epilepsy Research ·Samuel W. Terman, (unknown), (unknown), (unknown), Amanda Brand, (unknown), Neena Kalia, Margaret Dugan, (unknown), (unknown), (unknown), Palak Patel, James Burke, Arthur C. Grant, (unknown), Chloé E. Hill	1
2	Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score 2024 ·npj Precision Oncology ·(unknown), Andreas H. Scheel, Margaret Dugan, Robert Wild, (unknown), Barbara Holz, Johannes Brägelmann, Svenja Wagener‐Ryczek, Sabine Merkelbach‐Bruse, Juergen Wolf, Reinhard Büttner, (unknown), Matthias Scheffler, Axel M. Hillmer	0
3	Development of a rapid screener to elicit patient preferences for antiseizure medication discontinuation 2024 ·Epilepsy & Behavior ·Samuel W. Terman, (unknown), (unknown), (unknown), Amanda Brand, (unknown), Neena Kalia, Margaret Dugan, (unknown), (unknown), (unknown), Palak Patel, James Burke, Arthur C. Grant, (unknown), Chloé E. Hill	2
4	KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC 2023 ·Journal of Thoracic Oncology ·(unknown), Margaret Dugan, Robert Wild, (unknown), Barbara Holz, Andreas H. Scheel, Johannes Brägelmann, Svenja Wagener‐Ryczek, Sabine Merkelbach‐Bruse, Juergen Wolf, Reinhard Buettner, (unknown), Matthias Scheffler, Axel M. Hillmer	11
5	Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial 2020 ·Cancer Research ·Connie Wong, Jason Baum, (unknown), Michael T. Beste, (unknown), Siyan Xu, Ying A. Wang, Tony Wang, Margaret F. Prescott, (unknown), Margaret Dugan, Paul M. Ridker, Anne‐Marie Martin, E. C. Svensson	63
6	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 2012 ·Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, (unknown), (unknown), Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	14
7	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma 2011 ·Cancer Chemotherapy and Pharmacology ·David A. Reardon, Timothy F. Cloughesy, Jeremy N. Rich, W.K. Alfred Yung, Lotus Yung, Clifford DiLea, (unknown), Margaret Dugan, William Mietlowski, Andrea Maes, Charles A. Conrad	11
8	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma 2008 ·Clinical Cancer Research ·Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, (unknown), Monica Mita, Joachim Beck, Howard A. Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth W. Culver, Ricky W. Johnstone, H. Miles Prince	244
9	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib 2008 ·Haematologica ·Paul La Rosée, (unknown), Helmut König, Nicolai Härtel, Thomas Ernst, J. F. Debatin, Martin Mueller, Philipp Erben, Anja Binckebanck, Lydia Wunderle, Yaping Shou, Margaret Dugan, R. Hehlmann, Oliver G. Ottmann, Andreas Hochhaus	31
10	UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia 2007 ·Leukemia ·Jonathan B. Singer, Yaping Shou, Francis J. Giles, H Kantarjian, Yanzhi Hsu, Anna Robeva, P. Rae, Aaron Weitzman, Joanne M. Meyer, Margaret Dugan, Oliver G. Ottmann	91
11	702 POSTER Phase I pharmacokinetic and pharmacodynamic study of once-weekly IV LBH589 2007 ·European Journal of Cancer Supplements ·Shringi Sharma, N. Vogelzang, James S. Beck, Akash Patnaik, Monica Mita, Margaret Dugan, (unknown), Kenneth W. Culver, Peter Atadja, H. Miles Prince	5
12	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL breakdown → 2006 ·New England Journal of Medicine ·Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle, Kapil N. Bhalla, Susan O’Brien, Barbara Waßmann, Chiaki Tanaka, Paul W. Manley, P. Rae, William Mietlowski, (unknown), Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jörge E. Cortes, Leila Alland, Oliver G. Ottmann	970
13	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells 2005 ·Cancer ·Srđan Verstovšek, Mirna Golemović, Hagop M. Kantarjian, (unknown), Zeev Estrov, Paul W. Manley, Tong Sun, Ralph B. Arlinghaus, Leila Alland, Margaret Dugan, Jörge E. Cortes, Francis J. Giles, Miloslav Beran	55
14	Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials 2005 ·Annals of Oncology ·Joachim Drevs, Ute Zirrgiebel, (unknown), K. Mross, Michael Medinger, (unknown), José Cirı́aco Pinheiro, J M Wood, Anne Thomas, Clemens Unger, Andrew Henry, William P. Steward, Dirk Laurent, David Lebwohl, Margaret Dugan, Dieter Marmé	95
15	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia 2005 ·Clinical Cancer Research ·Mirna Golemović, Srđan Verstovšek, Francis J. Giles, Jörge E. Cortes, Taghi Manshouri, Paul W. Manley, Jürgen Mestan, Margaret Dugan, Leila Alland, James D. Griffin, Ralph B. Arlinghaus, Tong Sun, Hagop M. Kantarjian, Miloslav Beran	162
16	A PK-PD dose optimization strategy for the microtubule stabilizing agent ABJ879 2004 ·Cancer Research ·Clifford DiLea, Markus Wartmann, Sauveur-Michel Maira, Josef Brueggen, Chiaki Tanaka, Kurt C. Sizer, Margaret Dugan	1
17	Temozolomide in malignant gliomas of childhood 2002 ·Journal of Clinical Oncology ·L. S. Lashford, Philippe Thiesse, Anne Jouvet, T. Jaspan, D. Couanet, P. D. Griffiths, François Doz, James W. Ironside, (unknown), Rachel Hobson, Margaret Dugan, Andrew D.J. Pearson, Gilles Vassal, Didier Frappaz	2
18	Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study breakdown → 2001 ·Annals of Oncology ·W. Eiermann, Stefan Paepke, (unknown), Antonio Llombart‐Cussac, J. Eremin, J. Vinholes, L. Mauriac, Matthew J. Ellis, M. Lassus, Hilary A. Chaudri‐Ross, Margaret Dugan, (unknown), Semiglazov Vf	530
19	Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. 1993 ·Journal of Clinical Oncology ·Margaret Dugan, Damon Choy, A. Ngai, Jonathan S. T. Sham, Peter Choi, W. Shiu, Thomas W. T. Leung, P. Teo, U. Prasad, (unknown)	30
20	Global status of clinical photodynamic therapy: The registration process for a new therapy 1992 ·Lasers in Surgery and Medicine ·Stuart L. Marcus, Margaret Dugan	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact